Sprint PNS Now Covered by Aetna, What It Means for Chronic Pain Patients

In March 2026, Aetna updated its clinical policy. It now covers Sprint Peripheral Nerve Stimulation (PNS) for specific chronic pain conditions. This therapy is temporary and does not need a permanent implant. This is a meaningful development for patients who have tried physical therapy, medications, and injections without lasting relief. The post on osteopathic medicine and the chronic pain crisis explains why so many patients exhaust conservative care without resolution.

Dr. Knopp has been performing Sprint PNS at Hartford HealthCare's Pain Treatment Center. The new Aetna coverage significantly expands who can access it. Here is what you need to know.

What Is Sprint PNS?

Sprint Peripheral Nerve Stimulation is a short-term (60-day) neuromodulation therapy. A thin wire electrode is placed near the affected peripheral nerve under ultrasound guidance. No surgery and no permanent implant are needed. A small external pulse generator worn on the body delivers mild electrical signals that interrupt pain transmission. You can find a full overview of the procedures Dr. Knopp offers for chronic pain, including Sprint PNS.

After 60 days, the electrode is removed in a brief office procedure. No hardware remains in the body.

This is categorically different from spinal cord stimulation (SCS), which involves a permanent implant near the spinal cord. Sprint PNS targets peripheral nerves, the nerves outside the spine. This makes it appropriate for localized pain that has not responded to conservative treatment.

What the Evidence Shows

The largest dataset is a retrospective review published in Pain Physician in 2023, covering 6,160 patients implanted with a Sprint PNS System between August 2019 and August 2022. Its headline figures are worth stating precisely, because they are easy to repeat inaccurately:

• 71% of patients (4,348 of 6,160) were responders, which the study defines as at least 50% pain relief and/or an improvement in quality of life. It is a combined measure, not a pain measure on its own.
• Among those responders, pain relief averaged 63%.
• The responder rate was largely consistent across nerve targets throughout the back and trunk, the upper and lower extremities, and the posterior head and neck.

Two things about how that data was gathered should travel with those numbers. It is a retrospective review rather than a trial, and the records come from the device manufacturer's own national database, which the authors list as a limitation. The study also did not assess pain medication usage or physical function, so it cannot tell you whether patients moved better or took fewer medications, only what happened to their reported pain and quality of life.

None of that makes 71% a bad number. A large real-world dataset showing consistent results across many nerve targets is genuinely useful, and it complements the smaller prospective trials rather than replacing them. But a patient deserves to know that the figure combines two different outcomes and comes from the manufacturer's own records.

Does the relief last after the device comes out?

This is the question patients ask most, and until recently the honest answer was that nobody had followed people long enough to say.

For chronic low back pain specifically, and only that, a 2025 follow-up study went back to patients from an earlier study who had reported meaningful improvement in pain, disability or pain interference one year after treatment. Thirty-seven were invited and 23 answered. Fifteen of them, 65% of those who answered and 41% of everyone invited, reported at least 30% less back pain than before treatment, an average of 4.7 years after treatment began.

That is encouraging, and it needs three caveats to be read correctly. It surveyed only people already known to have done well at one year, so it cannot tell you how many patients reach that point in the first place. It had no control group and was funded by the device manufacturer. And it used a 30% pain-reduction threshold, which is a lower bar than the 50% figure quoted above, so the two percentages are not measuring the same thing. It also studied low back pain alone and says nothing about shoulder, knee or foot pain.

What Conditions Qualify Under the New Aetna Policy?

Aetna's March 2026 policy covers Sprint PNS for intractable neuropathic pain. This is chronic pain that has not responded to other treatment. Coverage depends on the nature of the pain (peripheral, neuropathic, treatment-resistant). It is not based on a checklist of body parts.

In practice, this applies to specific peripheral nerve pain in commonly treated areas:

• Shoulder pain (including rotator cuff-related and post-surgical pain)
• Knee pain (including post-arthroplasty and osteoarthritic pain)
• Low back pain with a peripheral nerve component
• Foot and ankle pain that has failed conservative management

Aetna's criteria include chronic intractable pain that is refractory to conservative care. This care must include in-person physical therapy for at least 6 weeks in the past year, medications, and injection or surgical options. The policy also requires objective evidence of pathology, for example EMG and nerve conduction studies or diagnostic blocks of the affected nerve, with the specific nerve to be stimulated named. There must be no active drug addiction and no psychological contraindication. Sprint PNS is a temporary 60-day therapy, not a permanent implant. So Aetna's policy does not require a separate stimulation trial beforehand.

The policy is written around anatomically specific, peripheral nerve-mediated pain, with a named target nerve and objective evidence behind it. Diffuse pain that cannot be traced to a specific peripheral nerve does not fit that framing, which is the practical reason such cases are usually not approved.

How Dr. Knopp Determines Who Is a Candidate

Before recommending Sprint PNS, Dr. Knopp evaluates several factors:

• Pain localization. Is the pain specific enough to target a single peripheral nerve? A patient with diffuse back pain from a multi-level disc problem may not be an ideal candidate. A patient with well-localized shoulder pain from a suprascapular nerve distribution often is.
• Treatment history. Sprint PNS is not a first-line treatment. At least 3-6 months of documented conservative care is standard. This includes physical therapy and at least one image-guided injection.
• Diagnostic nerve block response. In most cases, Dr. Knopp will perform a diagnostic block of the target nerve first. A temporary reduction in pain of about half or more from that block is what he looks for before proceeding.
• Functional goals. The conversation focuses on what the patient wants to do again: return to work, sleep through the night, resume activity. It is not just about a target pain score.

What the 60-Day Treatment Looks Like

The procedure is performed at Hartford HealthCare's Pain Treatment Center in West Hartford. Here is the general sequence:

1. Placement (Day 1): A thin electrode wire is placed near the target nerve through a small introducer needle. Ultrasound and/or fluoroscopic guidance is used. The procedure takes 20-45 minutes. Most patients go home the same day.
2. Stimulation (Days 1-60): A small external pulse generator (worn on the body, roughly the size of a credit card) is connected to the electrode lead. Parameters are programmed and adjusted at follow-up visits. Most patients feel a mild buzzing or tingling rather than pain.
3. Removal (Day 60): The electrode is removed in a brief office procedure. No incision is needed. The wire is simply extracted.

Patients continue normal activity during the treatment period with minor restrictions (no submersion in water, no high-impact activity at the insertion site).

How Sprint PNS Differs from Permanent Spinal Cord Stimulation

This is one of the most common questions Dr. Knopp hears. The short answer: Sprint PNS is a diagnostic and therapeutic tool. SCS is a long-term commitment.

Sprint PNS is often used as a bridge or trial before deciding on a permanent implant. If 60 days of peripheral nerve stimulation provides significant relief, it supports the case that neuromodulation is the right pathway. It helps guide the decision about whether a permanent device makes sense.

It also serves as a standalone treatment. Some patients get relief that outlasts the 60-day course without needing anything further, which is what the four-year low back pain follow-up above was measuring. The mechanism is not settled. The working hypothesis in the published studies is that weeks of stimulation change how the central nervous system processes the pain signal, and that this change can outlast the device. That is a hypothesis about why the relief persists, not an established fact. For patients who are not Sprint PNS candidates, regenerative options like PRP may offer a non-surgical path forward. Patients considering injections for joint or tendon pain should also review the post on PRP versus cortisone, which covers why repeated steroid injections can make degenerative conditions worse over time.

How to Find Out If You Qualify

The first step is an evaluation at Dr. Knopp's West Hartford office. During that visit, he will review your imaging and treatment history. He will also do a hands-on exam to determine whether Sprint PNS is appropriate and whether the initial step should be a diagnostic nerve block first.

Sprint PNS is performed at Hartford HealthCare, so the hospital bills it through your insurance and handles any pre-authorization. If you have Aetna and meet the coverage criteria, that authorization is typically obtained before the placement procedure. Dr. Knopp's own West Hartford concierge practice does not bill insurance. The evaluation that determines whether you are a candidate is private-pay.